NL-OMON45177已完成不适用
CALM-FIM_EUR - CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBIUSHD* - A PROSPECTIVE MULTICENTER SAFETY STUDY - CALM-FIM_EUR
Vascular Dynamics, Inc. Clinical Research0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Baseline Screening Visit 1 - (Day 0 - 14) - Assessed on Day 14
- •1. Provided written informed consent;
- •2. >= 18 years of age and <= 80 years of age;
- •3. Office cuff SBP >= 160 mmHg measured per protocol instructions (Appendix IV) following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic unless patient has history of intolerance, ineffectiveness or contraindications. Any combination medications will be counted per the active ingredient. (For example, Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications);
- •4. Carotid duplex studies demonstrating no obstructive carotid disease or plaque
- •5. Renal artery imaging performed within the last 12 months showing no evidence of renal artery stenosis. Acceptable imaging modalities include renal duplex, magnetic resonance angiography, CT angiography, and selective or nonselective renal angiography depending on trial site diagnostic standards. In the absence of adequate imaging testing this inclusion criteria could also be met by obtaining a renal duplex prior to enrollment, or by performing nonselective renal angiography at the time of device implantation.
- •6. Compliant with medications (self-reported); and
- •7. For females (with child-bearing potential), a negative pregnancy test, and the use of a medically accepted method of birth control for the duration of the trial.;Baseline Screening Visit 2 - (Day 15 - 30) - Assessed on Day 30
- •1. No significant obstructive vascular disease or plaque on CTA or MRA of the aortic arch and great vessels;
- •2. Continued adherence to hypertension medications without anticipated changes; and
- •3. Continued office cuff SBP >= 160 mmHg despite at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic unless patient has history of intolerance, ineffectiveness or contraindications. Any combination medications will be counted per the active ingredient. (For example, Zestoretic (Lisinopril+HCTZ) equals two (2) anti-hypertensive medications).;Day of Procedure -
- •1. Continued adherence to hypertension medications without anticipated changes.
排除标准
- •Baseline Screening Visit 1 - (Day 0 - 14) - Assessed on Day 14
- •1.Known or clinically suspected baroreflex failure or autonomic neuropathy;
- •2.Hypertension secondary to an identifiable and treatable cause other than sleep apnea;
- •3.Arm circumference greater than 46cm and/or BMI >= 40;
- •4.Chronic atrial fibrillation or recurrent atrial fibrillation with episode within the last 12 months;
- •5.Vulnerable plaque or ulceration of any size in the carotid artery or aortic arch;
- •6.History of bleeding complications with dual anti-platelet therapy in the past or has known uncorrectable bleeding diathesis;
- •7.Current use of additional anticoagulation therapy. (Examples include vitamin K antagonists like warfarin, direct thrombin inhibitors, direct factor Xa inhibitors, thrombin IIa inhibitors like apixaban, rivaroxaban, dabigatran and etexilate;
- •8.Peptic ulcer disease with documented active ulcer or bleeding within the last year.
- •9.History of allergy to contrast dye that cannot be managed medically;
- •10.History of orthostatic hypotension;
- •11.History of syncope within the last six (6) months;
- •12.History of myocardial infarction or unstable angina within the past three (3) months;
- •13.History of cerebral vascular accident (stroke or TIA) within the past year;
- •14.Severe chronic kidney disease (calculated GFR < 30 ml/min);
- •15.Prior surgery, radiation, or endovascular stent placement in either carotid region;
- •16.Clinically significant structural valvular cardiac disease;
- •17.Moderate to severe reactive airway disease, chronic obstructive pulmonary disease, or primary pulmonary hypertension;
- •18.Uncompensated congestive heart failure or known severe reduction in left ventricular function (EF < 30%);
- •19.Uncontrolled co-morbid medical condition that would adversely affect participation in the trial;
- •20.Non-controlled diabetes mellitus;
- •21.Active infection within the last month;
- •22.Co-morbid condition that reduces life expectancy to less than one (1) year;
- •23.Mental health issues that would prohibit the subject*s availability to meet the Protocol requirements;
- •24.Currently taking an imidazoline receptor agonist or central sympathetic treatment;
- •25.Enrolled in a concurrent clinical trial;
- •26.Unable or unwilling to fulfill the protocol follow-up requirements;
- •27.Subject is a prisoner or member of other protected population;
- •28.Planned surgery or other procedure within the next six (6) months; or
- •29.Deep venous thrombosis (DVT) within the last year or documented recurrent DVT.;Baseline Screening Visit 2 - (Day 15 - 30) - Assessed on Day 30
- •1.ICA lumen diameters < 5 mm or > 11.75 mm.
- •2.Carotid hypersensitivity detected by carotid massage or typical history, as described in the Protocol (Appendix V); or
- •3.Significant aortoiliac or common femoral artery disease that will prohibit safe femoral access
- •4. Mean 24-hour ambulatory blood pressure < 130/80 mmHg.;Day of Procedure - Angiographic
- •1. Evidence of plaque, ulceration or any stenosis by angiographic evaluation in
- •orthogonal views of the carotid artery. Lumen diameters will be assessed to exclude
- •subjects with ICA lumen diameters smaller than 5 mm or larger than 11.75 mm.
- •2. Any plaque or ulceration on the arch angiogram involving the aortic arch and/or the
- •origin of the great vessels;
- •3. Inappropriate anatomy of the carotid bifurcation for deployment of the MobiusH
研究者
相似试验
招募中
不适用
CALM-DIEM_EUR - Controlling and Lowering Blood Pressure with the MobiusHD* - Defining Efficacy Markers ;CALM-DIEM_EUR Sub-study - Studying the Effect of the MobiusHDTM on Sympathetic Activity and Baroreflex Sensitivity;CALM-DIEM_HTN-HF Sub-study - Studying the Effect of the MobiusHD® System in Hypertensive Patients with mild Chronic Heart FailureDrug resistant high blood pressureRefractory hypertensionResistant HypertensionNL-OMON45889Vascular Dynamics, Inc.39
已完成
不适用
A treatment algorithm reduces perioperative blood loss in children with congenital stenotic heart diseaseD68.00DRKS00014663Herz- und Diabeteszentrum Nordrhein-Westfalen Universitätsklinik der Ruhr-Universität Bochum Institut für Laboratoriums- und Transfusionsmedizin627
已完成
2 期
Controlling And Lowering blood pressure with the MobiusHD device: STudying effects in A Randomized Trial.resistant hypertensiondrug resistant high blood pressure10057166NL-OMON47214Vascular Dynamics, Inc.80
已完成
4 期
BAIL-OUT: 'Bail-out Anticoagulation in coronary Intervention TriaL - OUTcomes': a randomised comparison of the real world use of bivalirudin versus abciximab as a 'bail out' anticoagulant following heparin in percutaneous coronary intervention with focus on patient safetyCoronary artery diseaseCirculatory SystemIschaemic heart diseasesISRCTN98978563niversity Hospitals of Leicester NHS Trust (UK)100
进行中（未招募）
1 期
Trial of the medication tranexamic acid for stopping intracerebral haemorrhage soon after the bleedEUCTR2020-004746-10-FIThe Florey Institute of Neuroscience and Mental Health326